Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
- PMID: 34254992
- DOI: 10.1001/jamainternmed.2021.4610
Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
Comment in
-
The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease.JAMA Intern Med. 2021 Oct 1;181(10):1281. doi: 10.1001/jamainternmed.2021.4622. JAMA Intern Med. 2021. PMID: 34254991 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical